Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

1.035 +0.035 (+3.53%)
Streaming Delayed Price Updated: 1:32 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cognition Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo - 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January - 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
Study conducted in collaboration with the Alzheimer’s Clinical Trials Consortium 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Here are the top movers in Monday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 ↗
Almost all of it was event-driven, while the bulk of these gains were made by small biopharma names. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Wondering what's happening in today's pre-market session? ↗
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Monday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
What's going on in today's session ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Friday's session: top gainers and losers ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Thursday's session: top gainers and losers ↗
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket ↗
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday that it will be acquired by global private equity firm Advent in an... 
Via Benzinga
News headline image
Cognition Therapeutics Surges 30% Pre-Market After FDA Backs Phase 3 Trial Design For Alzheimer's Drug ↗
Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.